PT  - JOURNAL ARTICLE
AU  - Yeh, Ting-Yu
AU  - Contreras, Gregory P.
TI  - Full vaccination is imperative to suppress SARS-CoV-2 delta variant mutation frequency
AID  - 10.1101/2021.08.08.21261768
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.08.21261768
4099  - http://medrxiv.org/content/early/2021/08/10/2021.08.08.21261768.1.short
4100  - http://medrxiv.org/content/early/2021/08/10/2021.08.08.21261768.1.full
AB  - Public distrust has undermined COVID-19 vaccine acceptance and has become a major public health issue in the battle against SARS-CoV-2 transmission globally. Here we present the first evidence that the vaccination coverage rate is inversely correlated to the mutation frequency of the SARS-CoV-2 delta variant in 16 countries (R2=0.878), strongly indicating that full vaccination against COVID-19 is critical to suppress emergent mutations. We also present a promising tool to forecast new COVID-19 outbreaks. The Tajima’s D test, an evolutionary algorithm, with a threshold value of -2.50 is shown to be an accurate predictor of new outbreaks. We recommend that universal vaccination, as well as mitigation strategies, and genomic surveillance continue to be employed to prevent further viral transmission.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patients were involved and no IRB was required in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes1.The World Health organization. Tracking SARS-CoV-2 variants. 2. Global Initiative on Sharing All Influenza Data. 3. Coronavirus (COVID-19) Vaccinations. Our World in Data. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ https://www.gisaid.org/ https://ourworldindata.org/covid-vaccinations